cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Omeros Corporation
11 own
26 watching
Current Price
$9.33
$0.15
(1.63%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
243.96M
52-Week High
52-Week High
13.60000
52-Week Low
52-Week Low
2.61000
Average Volume
Average Volume
0.52M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization243.96M
icon52-Week High13.60000
icon52-Week Low2.61000
iconAverage Volume0.52M
iconDividend Yield--
iconP/E Ratio--
What does the Omeros Corporation do?
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The company's preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Read More
How much money does Omeros Corporation make?
News & Events about Omeros Corporation.
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the late-breaker session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros website. The presentation, which details data from a pre-specified interim...
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the companys lead MASP-3 inhibitor, in complement-inhibitor-nave adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and...
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the...
Business Wire
1 year ago
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at...
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (Rayner) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the Agreement), pursuant to which Omeros sold its ophthalmology product OMIDRIA to Rayner in...
Frequently Asked Questions
Frequently Asked Questions
What is Omeros Corporation share price today?
plus_minus_icon
Can Indians buy Omeros Corporation shares?
plus_minus_icon
How can I buy Omeros Corporation shares from India?
plus_minus_icon
Can Fractional shares of Omeros Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Omeros Corporation stocks?
plus_minus_icon
What is today’s traded volume of Omeros Corporation?
plus_minus_icon
What is today’s market capitalisation of Omeros Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Omeros Corporation?
plus_minus_icon
What percentage is Omeros Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Omeros Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$9.33
$0.15
(1.63%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$33.35
$-0.11 (-0.33 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$2.21
$-0.05 (-2.21 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.23
$0.08 (3.72 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$3.68
$0.41 (12.54 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$33.35
$-0.11 (-0.33 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$2.21
$-0.05 (-2.21 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.23
$0.08 (3.72 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$3.68
$0.41 (12.54 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00